Sulforaphane inhibits proliferation and invasive activity of everolimus-resistant kidney cancer cells in vitro

Although the mechanistic target of rapamycin (mTOR) inhibitor, everolimus, has improved the outcome of patients with renal cell carcinoma (RCC), improvement is temporary due to the development of drug resistance. Since many patients encountering resistance turn to alternative/complementary treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Juengel, Eva, Maxeiner, Sebastian, Rutz, Jochen, Justin, Saira, Roos, Frederik, Khoder, Wael, Tsaur, Igor, Nelson, Karen, Bechstein, Wolf O., Haferkamp, Axel, Blaheta, Roman A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356730/
https://www.ncbi.nlm.nih.gov/pubmed/27863441
http://dx.doi.org/10.18632/oncotarget.13421

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356730/
https://www.ncbi.nlm.nih.gov/pubmed/27863441
http://dx.doi.org/10.18632/oncotarget.13421

Ejemplares similares